# BEUN and Medipol University Patent Four Tyrosine Kinase Inhibitor Candidates in Europe

- Published: 2026-11-06 16:31 UTC
- Section: Life & Health › Medicine
- Tags: tyrosine kinase inhibitors, cancer drug candidates, BEUN chemistry, in vitro cancer screening, European patent oncology
- URL: https://realtech.media/news/rt-e5bde31613cf64f1c9bace65_beun_and_medipol/

**Turkish researchers have synthesized four candidate molecules that suppressed lung, breast, and prostate cancer cells in in vitro tests.**

![BEUN and Medipol University Patent Four Tyrosine Kinase Inhibitor Candidates in Europe](https://sgzwpqqelzmajkcubgkl.supabase.co/storage/v1/object/public/rt-media/2026/11/13cfa9785a676f98.jpg)
*Son Dakika*

Researchers from Zonguldak Bülent Ecevit University (BEUN) and Istanbul Medipol University have secured a European patent for four newly synthesized candidate molecules designed for oncology therapeutics, as reported by Son Dakika [1]. The compounds were developed under a research initiative focused on the synthesis of novel tyrosine kinase inhibitors and the assessment of their biological activity [1]. The initial synthesis of the chemical structures was carried out in Zonguldak, while in vitro biological activity tests were conducted in Istanbul [1].

## Mechanism and In Vitro Activity

The initiative targeted tyrosine kinase enzymes, which regulate signaling pathways associated with cell growth, division, and metastasis [1]. By inhibiting these enzymatic targets, the synthesized chemical entities prevented the proliferation of cancer cell lines during laboratory evaluations [1].

According to the investigators, laboratory assays demonstrated marked antiproliferative effects against breast, prostate, and lung cancer cells [1]. The properties and binding behaviors of the four distinct compounds were characterized through both experimental and computational modeling methods [1].

## Intellectual Property and Development Pipeline

The project, supported by Scientific Research Projects (BAP) funding and ongoing since 2018, aims to reduce off-target side effects common to existing treatments while maintaining therapeutic efficacy [1]. Following an initial filing with the Turkish Patent and Trademark Office, the intellectual property rights for the four novel compounds have now been recognized by the European Patent Office [1].

The project remains at the preclinical in vitro stage [1]. For any of the four patented candidate molecules to progress toward clinical therapy, they will require further in vivo pharmacokinetic and toxicity testing before being evaluated in human clinical trials [1].

## Sources

1. [Son Dakika](https://www.sondakika.com/saglik/haber-beun-ve-medipol-un-gelistirdigi-kanser-ilaci-adayi-20400818)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-e5bde31613cf64f1c9bace65_beun_and_medipol/